RxDoctor Payments DataLook up a doctor →

Stephanie Simon, APRN

Family · Omaha, NENPI 1225562473

Payments from drug & device makers

$156,942in general payments, 2019–2025

Across 798 payments — averaging $196.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GRT US Holding, Inc.$99K
  • Averitas Pharma Inc.$38K
  • AbbVie$7K
  • Medtronic$4K
  • Boston Scientific$2K
  • Abbott$2K
  • plus $5K from 40 others

What the payments were for

  • Consulting fees$27,08817%
  • Speaking & faculty fees$73,97547%
  • Travel & lodging$41,54626%
  • Food & beverage$14,2359%
  • Education$990%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$156,942 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$85,863
Medicare patients
150
Services billed
1,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen800$967,706
OxycontinOxycodone Hcl232$128,496
NucyntaTapentadol Hcl68$107,218
Xtampza ErOxycodone Myristate220$107,105
ProlateOxycodone Hcl/Acetaminophen22$74,562
BelbucaBuprenorphine Hcl71$66,214
Nucynta ErTapentadol Hcl50$60,548
UbrelvyUbrogepant40$45,922
Nurtec OdtRimegepant Sulfate27$42,866
RelistorMethylnaltrexone Bromide18$42,723
Buprenorphine137$33,100
MovantikNaloxegol Oxalate74$31,226
ZtlidoLidocaine38$29,795
LinzessLinaclotide51$26,994
HorizantGabapentin Enacarbil24$24,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca, Nucynta Er$701$341,085409 claims
AbbVieUbrelvy, Linzess, Qulipta$7,367$89,917110 claims
Forte Bio-pharma LLCProlate$439$74,56222 claims
PfizerNurtec Odt$38$42,86627 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$663$42,72318 claims
Redhill Biopharma Inc.Movantik$71$31,22674 claims
Scilex Pharmaceuticals Inc.Ztlido$399$29,79538 claims
Arbor Pharmaceuticals, Inc.Horizant$44$24,37724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.

Other family in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →